Latest Articles

Publication Date
Spinal-Cord Stimulation for Intractable, Visceral Pain Associated With Endometriosis: Positive Results of a Feasibility Study.

Endometriosis, an estrogen-dependent chronic inflammatory disease, can cause visceral pain. Owing to its chronic nature, treatment can be challenging and insufficient in reducing all symptoms despite adequate management. Spinal-cord stimulation …

Published: Dec. 3, 2025, midnight
Infertility management in patients with bowel endometriosis: the current landscape and the promise of randomised trials: a narrative review.

The management of infertility in women with bowel endometriosis remains a significant clinical challenge. The two primary therapeutic approaches include first-line medically assisted reproduction (MAR) and primary bowel surgery, with …

Published: Dec. 3, 2025, midnight
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target.

Endometriosis is a chronic, heterogeneous disease with limited non-hormonal treatment options. Drug repurposing provides an accelerated route to identify safe, tolerable, and potentially effective therapies for endometriosis. Receptor tyrosine kinase-like …

Published: Dec. 3, 2025, midnight
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire

Published: Dec. 2, 2025, 1:05 p.m.
Bayer aims Mirena at women's health issue with no treatment - pharmaphorum

Bayer aims Mirena at women's health issue with no treatment pharmaphorum

Published: Dec. 2, 2025, 12:25 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer

Published: Dec. 2, 2025, 7:30 a.m.
The pelvic pain bias assessment: a new assessment of interpretation bias specific to pelvic pain.

Pelvic pain is a common and often debilitating experience with limited treatment options. Improving understanding of the psychosocial mechanisms involved in pelvic pain experiences will enhance the efficacy of pain …

Published: Dec. 2, 2025, midnight
High inhibition ratio and transformation index of 2 mg dienogest: further evidence for its use in endometriosis treatment.

Endometriosis is a common, chronic disease with a high burden for women, characterised by the implantation of endometrial cells outside the uterus. Many different treatments have been proposed for this …

Published: Dec. 2, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!